ES2371287T3 - Expresión diferencial de la citocina en cáncer humano. - Google Patents

Expresión diferencial de la citocina en cáncer humano. Download PDF

Info

Publication number
ES2371287T3
ES2371287T3 ES07764767T ES07764767T ES2371287T3 ES 2371287 T3 ES2371287 T3 ES 2371287T3 ES 07764767 T ES07764767 T ES 07764767T ES 07764767 T ES07764767 T ES 07764767T ES 2371287 T3 ES2371287 T3 ES 2371287T3
Authority
ES
Spain
Prior art keywords
tumor
cytokine
agent
cells
neutralizing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07764767T
Other languages
English (en)
Spanish (es)
Inventor
Giorgio Stassi
Christian Gieffers
Oliver Hill
Meinolf Thiemann
Matilde Todaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG filed Critical Apogenix AG
Application granted granted Critical
Publication of ES2371287T3 publication Critical patent/ES2371287T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
ES07764767T 2006-06-21 2007-06-21 Expresión diferencial de la citocina en cáncer humano. Active ES2371287T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012754 2006-06-21
EP06012754 2006-06-21

Publications (1)

Publication Number Publication Date
ES2371287T3 true ES2371287T3 (es) 2011-12-29

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07764767T Active ES2371287T3 (es) 2006-06-21 2007-06-21 Expresión diferencial de la citocina en cáncer humano.

Country Status (12)

Country Link
US (1) US20090324616A1 (https=)
EP (1) EP2041576B1 (https=)
JP (1) JP2010514409A (https=)
CN (1) CN101529253A (https=)
AT (1) ATE520032T1 (https=)
AU (1) AU2007263265A1 (https=)
BR (1) BRPI0713484A2 (https=)
CA (1) CA2656379A1 (https=)
DK (1) DK2041576T3 (https=)
ES (1) ES2371287T3 (https=)
RU (1) RU2009101783A (https=)
WO (1) WO2007147600A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
AU2015335607B2 (en) * 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
EP4053557A1 (en) * 2016-11-24 2022-09-07 Huvet Bio, Inc. Il-29 as a marker for a pancreatic disease
CN111051349A (zh) * 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1995007301A1 (en) 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
AU686816B2 (en) * 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1824886B1 (en) * 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy

Also Published As

Publication number Publication date
WO2007147600A2 (en) 2007-12-27
EP2041576A2 (en) 2009-04-01
BRPI0713484A2 (pt) 2012-11-06
EP2041576B1 (en) 2011-08-10
RU2009101783A (ru) 2010-07-27
ATE520032T1 (de) 2011-08-15
DK2041576T3 (da) 2011-12-05
JP2010514409A (ja) 2010-05-06
CN101529253A (zh) 2009-09-09
US20090324616A1 (en) 2009-12-31
CA2656379A1 (en) 2007-12-27
AU2007263265A1 (en) 2007-12-27
WO2007147600A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
ES2371287T3 (es) Expresión diferencial de la citocina en cáncer humano.
Silva-Santos et al. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Wei et al. Tumor microenvironment regulation by the endoplasmic reticulum stress transmission mediator Golgi protein 73 in mice
ES2813360T3 (es) Diana terapéutica y diagnóstica para el cáncer que comprende reactivos de unión a DLL3
ES2420582T3 (es) La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
US20150118244A1 (en) Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
JP2006519190A (ja) サイトカインを選択的にブロックすることによる、アポトーシスに対する感作細胞
JP7032396B2 (ja) Ｔ細胞応答を促進するための方法
JP2016501843A (ja) 癌治療および判断ターゲットとしてのｌｙ７５
CA3076997C (en) Anti-ckap4 monoclonal antibody
US20190351024A1 (en) Immunocytokines with progressive activation mechanism
Kiewlich et al. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth
CN101679485B (zh) 骨桥蛋白的功能表位、针对该单位的单克隆抗体及它们的应用
KR20140004552A (ko) 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물
Liu et al. Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma
US20220056123A1 (en) Use of il-1beta binding antibodies
ES2937862T3 (es) Predicción de respondedores a terapia con ciclofosfamida
ES2868998T3 (es) Anticuerpo biespecífico que se une a NAALADL2 Y CD3 para el uso como agente terapéutico en el tratamiento del cáncer de próstata
US10604585B2 (en) Modulation of PTPRA to treat arthritis
EP4729544A1 (en) Use of claudin-3 as target for diagnosis and treatment of small cell lung cancer
Ozaki et al. IL25+ macrophages are a key determinant of treatment resistance of IL17RB+ breast cancer
JP2011522872A (ja) エフリンａ型受容体７タンパク質
CN107604064B (zh) Ccl20在肿瘤化疗疗效评估和肿瘤治疗中的应用
Gameiro Improving feline mammary carcinoma treatment through HER2-related immunochemotherapy agents and biomarkers
KR20120109824A (ko) Ｐａｕｆ 및 그의 결합 파트너를 상호작용을 이용한 암 치료제의 스크리닝 방법